Glycan News and Research

RSS

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

Toxoplasma remodels host cell surfaces to trigger invasion

At first, cholesterol and glycosylation seemed like two separate leads. As the researchers followed them, however, the pathways converged.

25 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

Fleeting interactions between membrane sugar chains control cell division

Acting as an armor, a scaffold, and a communication platform in one, our cells' plasma membrane lies at the heart of many crucial cellular processes.

27 Aug 2026

'Locked' cancer therapeutic safely shrinks breast tumors in mice

Although there are many cancer treatments available today that effectively eliminate abnormal cells, these therapies may also damage healthy cells, leading to unwanted side effects.

13 Aug 2026

Long-acting HIV prevention tools could help close the gap before a vaccine arrives

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, vertical transmission programs, and voluntary medical male circumcision. Gene editing and multispecific antibodies may expand future options, but safety, cost, access, adherence, and implementation barriers remain.

5 Aug 2026

Scientists find mechanism behind bird flu infections in dairy cattle

When H5N1 bird flu first began infecting U.S. cattle in early 2024, diagnosis was elusive, because in cows, the disease looked completely different.

19 Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

14 Jun 2026

Flu drugs may reduce cognitive decline in people with HIV

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and extended into preclinical drug trials.

5 Jun 2026

Boston Children's scientists create new booster-free mRNA vaccine strategy

In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the original COVID-19 mRNA vaccine with an immune system enhancer, known as an adjuvant, extended the duration of the vaccine's protection in mice from a few months up to two years.

22 May 2026

New non invasive way to diagnose childhood epilepsy through blood sugar patterns

A study published in Engineering has demonstrated that the N-glycome of serum-derived extracellular vesicles (EVs) can serve as a non-invasive biosignature for the diagnosis and classification of childhood epilepsy, offering a new tool for precision and longitudinal monitoring in clinical settings.

14 May 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

Bruker advances Functional Proteomics 2.0 with timsOmni™ mass spectrometry proteoform analysis for deeper insights into disease biology

Bruker Corporation today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants.

From Bruker Daltonics 24 Feb 2026